ALLERGAN ANNOUNCES FINAL EXTENSION OF INAMED EXCHANGE OFFER AND AMENDMENT TO MERGER AGREEMENT

Allergan, Inc. today announced that it is extending the expiration date of its exchange offer for all outstanding shares of common stock of Inamed Corporation. All conditions to the completion of the exchange offer currently are satisfied. However, Allergan is extending the offer pursuant to its one-time right under its merger agreement with Inamed to extend the offer for up to five business days to seek valid tenders representing at least 90% of the outstanding Inamed common stock so that it can complete the acquisition through a short-form merger under Delaware law.
Genetic Engineering News